Immuron trims at-the-market offering capacity to about $2 million
The company filed a prospectus supplement reducing the amount it can sell under its ATM agreement with H.C. Wainwright to roughly $2,006,769.
SEC filing
3 stories
The company filed a prospectus supplement reducing the amount it can sell under its ATM agreement with H.C. Wainwright to roughly $2,006,769.
SEC filing
Neogen lifted full-year guidance after first-quarter core revenue grew 8.1% and said Petrifilm manufacturing and a pending Zoetis divestiture remain on schedule.
SEC filing (11)
The Australian biopharma outlined FY26 revenue growth, a partnering strategy for two clinical assets, and FDA clearance for an IMM-529 Phase 2 study.
SEC filing